These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 34161667)

  • 1. Performance status as prognostic factor in phase III trials of first-line chemotherapy of unresectable or metastatic pancreatic cancer: A trial-level meta-analysis.
    Colloca G
    Asia Pac J Clin Oncol; 2022 Jun; 18(3):232-239. PubMed ID: 34161667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Effect of Performance Status on Outcomes of Patients with Colorectal Cancer Receiving First-Line Chemotherapy: A Meta-analysis.
    Colloca GA; Venturino A
    J Gastrointest Cancer; 2024 Mar; 55(1):418-426. PubMed ID: 37966630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FOLFIRINOX in patients with peritoneal carcinomatosis from pancreatic adenocarcinoma: a retrospective study.
    Bonnet E; Mastier C; Lardy-Cléaud A; Rochefort P; Sarabi M; Guibert P; Cattey-Javouhey A; Desseigne F; de La Fouchardière C
    Curr Oncol; 2019 Aug; 26(4):e466-e472. PubMed ID: 31548814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic value of Eastern Cooperative Oncology Group performance status on overall survival among patients with metastatic prostate cancer: a systematic review and meta-analysis.
    Assayag J; Kim C; Chu H; Webster J
    Front Oncol; 2023; 13():1194718. PubMed ID: 38162494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second-generation inflammation-related scores are more effective than systemic inflammation ratios in predicting prognosis of patients with unresectable or metastatic pancreatic cancer receiving cytotoxic chemotherapy.
    Colloca GA; Venturino A; Guarneri D
    Med Oncol; 2018 Oct; 35(12):158. PubMed ID: 30374617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.
    Reck M; Thatcher N; Smit EF; Lorigan P; Szutowicz-Zielinska E; Liepa AM; Winfree KB; Peterson P; Guba SC; Socinski MA
    Lung Cancer; 2012 Dec; 78(3):276-81. PubMed ID: 23043970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2? A meta-analysis of published trials.
    Iacovelli R; Altavilla A; Procopio G; Bracarda S; Santoni M; Cascinu S; Cortesi E
    Prostate Cancer Prostatic Dis; 2013 Dec; 16(4):323-7. PubMed ID: 23896627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use and outcomes of chemotherapy for metastatic pancreatic cancer in Australia.
    Body A; Wong R; Shapiro J; Jalali A; McLachlan SA; Ananda S; Lipton L; Cooray P; Gibbs P; Lee B; Lee M
    Intern Med J; 2022 Jan; 52(1):49-56. PubMed ID: 33040452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective analysis by site of primary tumor of patients with unresectable locally-advanced or metastatic pancreatic adenocarcinoma receiving chemotherapy.
    Colloca GA; Venturino A; Guarneri D
    Clin Exp Metastasis; 2019 Dec; 36(6):519-525. PubMed ID: 31578654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prognostic model to identify patients with advanced pancreas adenocarcinoma who could benefit from second-line chemotherapy.
    Kim ST; Choi YJ; Park KH; Oh SC; Seo JH; Shin SW; Kim JS; Kim YH
    Clin Oncol (R Coll Radiol); 2012 Mar; 24(2):105-11. PubMed ID: 21382702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Palliative chemotherapy for gastroesophageal cancer in old and very old patients: A retrospective cohort study at the National Center for Tumor Diseases, Heidelberg.
    Berger AK; Zschaebitz S; Komander C; Jäger D; Haag GM
    World J Gastroenterol; 2015 Apr; 21(16):4911-8. PubMed ID: 25945004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors.
    Vivaldi C; Caparello C; Musettini G; Pasquini G; Catanese S; Fornaro L; Lencioni M; Falcone A; Vasile E
    Int J Cancer; 2016 Aug; 139(4):938-45. PubMed ID: 27038273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ECOG performance score 0 versus 1: impact on efficacy and safety of first-line 5-FU-based chemotherapy among patients with metastatic colorectal cancer included in five randomized trials.
    Abdel-Rahman O
    Int J Colorectal Dis; 2019 Dec; 34(12):2143-2150. PubMed ID: 31732876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer.
    Hwang JE; Kim HN; Kim DE; Choi HJ; Jung SH; Shim HJ; Bae WK; Hwang EC; Cho SH; Chung IJ
    BMC Cancer; 2011 Nov; 11():489. PubMed ID: 22103888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials: A Systematic Review and Meta-analysis.
    Yang F; Markovic SN; Molina JR; Halfdanarson TR; Pagliaro LC; Chintakuntlawar AV; Li R; Wei J; Wang L; Liu B; Nowakowski GS; Wang ML; Wang Y
    JAMA Netw Open; 2020 Aug; 3(8):e2012534. PubMed ID: 32766800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of prognostic factors and applicability of Kohne's prognostic groups in patients with metastatic colorectal cancer treated with first-line irinotecan or oxaliplatin-based chemotherapy.
    Díaz R; Aparicio J; Gironés R; Molina J; Palomar L; Segura A; Montalar J
    Clin Colorectal Cancer; 2005 Sep; 5(3):197-202. PubMed ID: 16197623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.
    Zaanan A; Shi Q; Taieb J; Alberts SR; Meyers JP; Smyrk TC; Julie C; Zawadi A; Tabernero J; Mini E; Goldberg RM; Folprecht G; Van Laethem JL; Le Malicot K; Sargent DJ; Laurent-Puig P; Sinicrope FA
    JAMA Oncol; 2018 Mar; 4(3):379-383. PubMed ID: 28983557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multimodal Treatment with GEMOX Plus Helical Tomotherapy in Unresectable Locally Advanced Pancreatic Cancer: A Pooled Analysis of Two Phase 2 Studies.
    Passardi A; Rapposelli IG; Scarpi E; Sullo FG; Bartolini G; Neri E; Ghigi G; Tontini L; Ercolani G; Monti M; Ruscelli S; Matteucci L; Valgiusti M; Frassineti GL; Romeo A
    Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors for 60-day mortality in first-line treatment of metastatic colorectal cancer (mCRC): individual patient analysis of four randomised, controlled trials by the AIO colorectal cancer study group.
    Giessen C; Graeven U; Laubender RP; Modest DP; Schulz C; Porschen R; Schmiegel W; Reinacher-Schick A; Hegewisch-Becker S; Stintzing S; Heinemann V
    Ann Oncol; 2013 Dec; 24(12):3051-5. PubMed ID: 24130263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of health-related quality of life in patients with metastatic pancreatic adenocarcinoma: a random forest methodology.
    Diouf M; Filleron T; Pointet AL; Dupont-Gossard AC; Malka D; Artru P; Gauthier M; Lecomte T; Aparicio T; Thirot-Bidault A; Lobry C; Fein F; Dubreuil O; Landi B; Zaanan A; Taieb J; Bonnetain F
    Qual Life Res; 2016 Jul; 25(7):1713-23. PubMed ID: 26615615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.